Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Intra-Cellular Therapies reports robust Q1 performance and advances pipeline programs

ITCI's Q1 performance reflects significant growth for CAPLYTA and positive study results for treating MDD and bipolar depression with mixed features. The company's strong financial position, ongoing pipeline progress, and plans for future filings indicate a promising outlook. However, challenges in obtaining market share information and addressing unmet needs in patient populations require careful consideration.

ITCI reports robust Q2 performance, anticipates growth from antidepressant effects

ITCI's Q2 2023 performance reflects strong demand for CAPLYTA and a positive outlook for future net product sales. The company's financial stability and promising developments in the antidepressant effects of Lumateperone position it well for continued growth, despite potential challenges in program prioritization and ongoing studies.

ITCI reports robust Q3 results, eyes expansion opportunities for CAPLYTA

ITCI's Q3 performance reflects robust growth in CAPLYTA prescriptions and net sales, positioning the company for continued financial strength. While facing challenges in expanding indications and generating clinical data, opportunities in potential MDD approval and label expansion present avenues for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Developer of treatments for neuropsychiatric and neurologic disorders, Intra-Cellular Therapies (NYSE: ITCI) today had a large opening gap of -22.59%.

What Caused The Opening Gap In Intra-Cellular Therapies?

Intra-Cellular Therapies Inc. (NASDAQ: ITCI) shares dipped on Monday after the company announced top-line results from its two late-stage trial in patients with bipolar depression.

Why Intra-Cellular Therapies’ Depression Study Is Nothing to Smile About

Shares of biotech Intra-Cellular Therapies ITCI, -1.10% fell 15% in premarket trade Monday after the company announced disappointing results from a late-stage trial of its lead drug candidate lumateperone, a potential bipolar depression treatment.

Intra-Cellular Therapies stock down 15% after disappointing Phase 3 trial results

Intra-Cellular Therapies (NASDAQ: ITCI) shares resumed trading after the company released mixed study results from two Phase 3 clinical trials evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with bipolar depression.

Intra-Celluar Therapies Falls Following Results For Treatment Of Bipolar Depression

Intra-Cellular Therapies Inc. icti on Monday reported positive results from two late-stage trials of a treatment for bipolar depression.

Intra-Cellular announces positive results in late-stage trials of treatment for bipolar depression

AngioDynamics

Biotech stocks saw muted sentiment in the holiday-shortened week ending July 5 after a strong rebound in the later part of the previous week.

The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings

Acer Therapeutics

Biohaven Pharmaceutical Hld

Celgene

Karyopharm Therapeutics

Merck

The FDA went overdrive in the month of June, deciding on several regulatory applications before the July 4 holiday.

Attention Biotech Investors: Mark Your Calendar For These July 2019 PDUFA Dates

Chemical Financial

Golden Entertainment

Guess?

Occidental Petroleum

Park-Ohio Holdings

Sharps Compliance

There are many reasons why an insider may sell their company's stock. But they only buy it for one reason -- to profit.

7 Stocks on Sale the Insiders Are Buying.

Despite one failed Phase 3 trial, Intra-Cellular Therapeutics lead candidate for schizophrenia (ITI-007) appears headed for approval in September 2019, owing to its superior safety and tolerability profile versus standard-of-care.

Intra-Cellular Therapies: Key Catalyst On The Horizon

Intra-Cellular Therapies Inc. (ITCI) CEO Sharon Mates on Q1 2019 Results - Earnings Call Transcript

Intra-Cellular could be the first company to fully transform anti-depressant market.

Intra-Cellular Therapies: A Blossoming Lotus

News for Intra-Cellular Therapies Stock (ITCI)